Savara Inc (NASDAQ:SVRA) Shares Bought by Frazier Life Sciences Management L.P.

Frazier Life Sciences Management L.P. grew its position in shares of Savara Inc (NASDAQ:SVRA) by 103.9% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,157,385 shares of the company’s stock after purchasing an additional 4,157,385 shares during the quarter. Savara makes up about 1.5% of Frazier Life Sciences Management L.P.’s portfolio, making the stock its 21st biggest holding. Frazier Life Sciences Management L.P. owned 0.06% of Savara worth $32,874,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Superstring Capital Management LP purchased a new stake in shares of Savara in the fourth quarter valued at approximately $3,827,000. Wellington Management Group LLP purchased a new position in Savara in the 4th quarter valued at $9,683,000. Sivia Capital Partners LLC acquired a new stake in Savara during the 4th quarter worth $169,000. China Universal Asset Management Co. Ltd. grew its holdings in shares of Savara by 66.3% during the first quarter. China Universal Asset Management Co. Ltd. now owns 26,035 shares of the company’s stock worth $130,000 after buying an additional 10,381 shares in the last quarter. Finally, BNP Paribas Financial Markets grew its holdings in shares of Savara by 92.3% during the first quarter. BNP Paribas Financial Markets now owns 73,494 shares of the company’s stock worth $366,000 after buying an additional 35,269 shares in the last quarter. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on SVRA. Guggenheim raised their price target on shares of Savara from $8.00 to $10.00 and gave the stock a “buy” rating in a research note on Thursday, June 27th. JMP Securities reissued a “market outperform” rating and issued a $9.00 price target on shares of Savara in a research note on Monday, September 9th. HC Wainwright reissued a “buy” rating and issued a $10.00 price target on shares of Savara in a research note on Wednesday, August 14th. Finally, Oppenheimer raised their price target on shares of Savara from $11.00 to $15.00 and gave the stock an “outperform” rating in a research note on Wednesday, June 26th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Savara has a consensus rating of “Buy” and an average price target of $11.17.

Savara Price Performance

Savara stock opened at $4.24 on Friday. Savara Inc has a 12-month low of $3.12 and a 12-month high of $5.70. The stock has a market cap of $585.92 million, a P/E ratio of -11.46 and a beta of 0.97. The company has a 50-day moving average price of $4.34 and a 200 day moving average price of $4.47. The company has a current ratio of 11.31, a quick ratio of 11.31 and a debt-to-equity ratio of 0.26.

Savara (NASDAQ:SVRA) last released its quarterly earnings data on Monday, August 12th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.01). Sell-side analysts anticipate that Savara Inc will post -0.44 earnings per share for the current year.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.